PURPOSE: This study examined caffeine (CAF) effects on physical performance and vigilance during 4 d and 3 nights of sustained operations in Special Forces personnel. METHODS: There were 20 soldiers (28.6 +/- 4.7 yr, 177.6 +/- 7.5 cm, 81.2 +/- 8.0 kg) who were divided equally into placebo (PLAC) and CAF groups. A 4-km run that included three obstacles (OBST) was completed each morning with the performance on Day 2 representing control (CON) after familiarization on Day 1 and an 8-h sleep. From 01:30 to 06:15 of Days 3-5, soldiers performed two 2-h vigilance (VIG) sessions in the field. PLAC or 200 mg of CAF was administered at 21:45 of Days 2-4 and at 01:00, 03:45, and approximately 07:00 on Days 3-5. The run commenced within 30 min of the final dose. Soldiers were provided a 4-h sleep period from 13:30-17:30 during Days 3 and 4. RESULTS: VIC during Days 3-5 was greater for CAF vs. PLAC and not different from CON. Total run time was faster for CAF (29.7 +/- 2.0 min) compared with PLAC (30.7 +/- 2.9 min) on Day 3 due to faster completion of OBST (8.7 +/- 0.7 min vs. 9.2 +/- 1.0 min for CAF and PLAC, respectively). Thereafter, run times decreased for both groups on Days 4 and 5 compared with CON due primarily to an increased pace between OBST. CONCLUSIONS: it was concluded that CAF maintained both vigilance and physical performance during sustained operations that require periods of overnight wakefulness and restricted opportunities for daytime sleep.
RCT Entities:
PURPOSE: This study examined caffeine (CAF) effects on physical performance and vigilance during 4 d and 3 nights of sustained operations in Special Forces personnel. METHODS: There were 20 soldiers (28.6 +/- 4.7 yr, 177.6 +/- 7.5 cm, 81.2 +/- 8.0 kg) who were divided equally into placebo (PLAC) and CAF groups. A 4-km run that included three obstacles (OBST) was completed each morning with the performance on Day 2 representing control (CON) after familiarization on Day 1 and an 8-h sleep. From 01:30 to 06:15 of Days 3-5, soldiers performed two 2-h vigilance (VIG) sessions in the field. PLAC or 200 mg of CAF was administered at 21:45 of Days 2-4 and at 01:00, 03:45, and approximately 07:00 on Days 3-5. The run commenced within 30 min of the final dose. Soldiers were provided a 4-h sleep period from 13:30-17:30 during Days 3 and 4. RESULTS: VIC during Days 3-5 was greater for CAF vs. PLAC and not different from CON. Total run time was faster for CAF (29.7 +/- 2.0 min) compared with PLAC (30.7 +/- 2.9 min) on Day 3 due to faster completion of OBST (8.7 +/- 0.7 min vs. 9.2 +/- 1.0 min for CAF and PLAC, respectively). Thereafter, run times decreased for both groups on Days 4 and 5 compared with CON due primarily to an increased pace between OBST. CONCLUSIONS: it was concluded that CAF maintained both vigilance and physical performance during sustained operations that require periods of overnight wakefulness and restricted opportunities for daytime sleep.
Authors: Sridhar Ramakrishnan; Nancy J Wesensten; Gary H Kamimori; James E Moon; Thomas J Balkin; Jaques Reifman Journal: Sleep Date: 2016-10-01 Impact factor: 5.849
Authors: Devon A Hansen; Sridhar Ramakrishnan; Brieann C Satterfield; Nancy J Wesensten; Matthew E Layton; Jaques Reifman; Hans P A Van Dongen Journal: Psychopharmacology (Berl) Date: 2018-12-11 Impact factor: 4.530
Authors: Nanci S Guest; Trisha A VanDusseldorp; Michael T Nelson; Jozo Grgic; Brad J Schoenfeld; Nathaniel D M Jenkins; Shawn M Arent; Jose Antonio; Jeffrey R Stout; Eric T Trexler; Abbie E Smith-Ryan; Erica R Goldstein; Douglas S Kalman; Bill I Campbell Journal: J Int Soc Sports Nutr Date: 2021-01-02 Impact factor: 5.150
Authors: Erica R Goldstein; Tim Ziegenfuss; Doug Kalman; Richard Kreider; Bill Campbell; Colin Wilborn; Lem Taylor; Darryn Willoughby; Jeff Stout; B Sue Graves; Robert Wildman; John L Ivy; Marie Spano; Abbie E Smith; Jose Antonio Journal: J Int Soc Sports Nutr Date: 2010-01-27 Impact factor: 5.150
Authors: Ninad S Chaudhary; Brittany V Taylor; Michael A Grandner; Wendy M Troxel; Subhajit Chakravorty Journal: Pharmacol Biochem Behav Date: 2021-05-15 Impact factor: 3.697
Authors: Gary H Kamimori; Tom M McLellan; Charmaine M Tate; David M Voss; Phil Niro; Harris R Lieberman Journal: Psychopharmacology (Berl) Date: 2014-12-21 Impact factor: 4.530